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Stroke is a prototype disorder that disables as well as kills people. The disability-adjusted life 
years (DALY) metric developed by the World Health Organization to measure the global burden 
of disease integrates healthy life years lost due to both premature mortality and living with dis-
ability. Accordingly, it is well suited to stroke research. The DALY has previously been applied 
only to large but relatively crude population-level data analyses, but now it is possible to calculate 
the DALY lost in individual stroke patients. Measuring each patient’s stroke outcome with DALY 
lost has expanded its application to the analysis of treatment effect in acute stroke trials, delineat-
ing the poststroke complication impact, the differential weighting of discrete vascular events, and 
estimating a more refined stroke burden in a specific population. The DALY metric has several 
advantages over conventional stroke outcome measures: 1) Since the DALY measures the burden 
of diverse health conditions with a common metric of life years lost, stroke burden and benefits of 
stroke interventions can be directly compared to other health conditions and their treatments. 2) 
Quantifying stroke burden or interventional benefits as the life years lost or gained makes the 
DALY metric more intuitively accessible for public and health system planners. 3) As a continu-
ous, equal-interval scale, the DALY analysis might be statistically more powerful than either bi-
nary or ordinal rank outcome analyses in detecting the treatment effects of clinical trials. 4) While 
currently employed stroke outcome measures take one-time snapshots of disability or mortality 
and implicitly indicate long-term health impact, the DALY explicitly indicates the burdens of liv-
ing with disability for an individual’s remaining life.  J Clin Neurol 2011;7:109-114
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Introduction
Incidence, mortality, and prevalence have traditionally been 
employed to measure the societal burden of disease. Incidence 
and prevalence measures can indicate disease quantity but fail 
to capture disease severity or intensity. Mortality can partially 
indicate disease severity but cannot incorporate nonfatal health 
conditions that disable human beings for their residual life. 
Moreover, the epidemiological transition from infectious and 
nutritional diseases to chronic and degenerative diseases has 
called for a paradigm shift in measuring disease burden to in-
corporate disability. 
In 1992, the World Health Organization (WHO), the World 
Bank, and Harvard School of Public Health cooperated to de-
velop a new metric of disability-adjusted life years (DALY) to 
quantify the burden of disease and injury on human beings for 
the Global Burden of Disease Project (GBDP).
1,2 The DALY 
is a time-based measure of health status that incorporates both 
disability and mortality. Employing the time lost as a common, 
universal measurement unit enables a comparison of relative 
burdens of diverse health conditions and guides health-system 
planning.
To integrate disability into disease burden, the WHO-GBDP 
developed a concept of disability weight (DW) to rate nonfatal 
health conditions. The DW is a weighting factor that reflects 
the severity of the disease on a scale from 0 (perfect health) to 
1 (equivalent to death).
1,3 Using the person-trade-off method, 
healthcare professionals who participated in the WHO-GBDP 
judged each health status from a broad health perspective, en-
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suring equity across various health conditions, and determined 
DWs for more than 400 health conditions. Using DWs and po-
pulation-level data of incidence, prevalence, and fatality, the 
WHO-GBDP has measured the burden of hundreds of diseas-
es and injuries globally and regionally in a metric of DALY. 
The DALY has also been applied to a cost-effective analysis 
of an interventional efficacy on a population level.
4,5 However, 
since it was not possible to directly calculate DALY lost to a 
disease in an individual patient, the application of DALY has 
been limited to population-level data analyses.
Previously, only a unified DW was available for chronic 
poststroke states, despite its wide range of disability.
3 Formal-
ly derived fine-grained DWs for each modified Rankin Scale 
(mRS) disability level are now available.
6 In addition, a novel 
methodology enables the estimation of the life expectancies of 
stroke survivors based on their age, gender and mRS disabili-
ty levels.
7,8 As a result, it is possible to derive individual pati-
ents’ DALY lost to stroke, and the DALY application has been 
expanded to diverse stroke research areas.
This review discusses the DALY concept and its applica-
tions to acute stroke trials, secondary prevention trials, regis-
try-based outcome research, and a new approach to estimate a 
nationwide stroke burden.
The DALY concept and derivation
DALY lost is the sum of years of life lost due to premature 
death (YLL) and years of healthy life lost due to disability 
(YLD): DALY=YLL+YLD.
1 One DALY lost indicates 1 year 
lost of healthy life. Conceptually, since the YLL is the loss of 
life years due to premature death caused by a fatal disease or 
disability impact, the YLL of a stroke patient who dies at age 
A is equal to a life expectancy of general population at age A. 
For living with a DW [range from 0 (normal health without 
disability) to 1 (equivalent to death)] for Ld years, YLD=(DW)× 
Ld. Living for Ld years without disability (DW=0) would be a 
YLD of 0. As an example, a 60-year-old man has a stroke, lives 
for 10 years with a DW of 0.4, and the life expectancy of gen-
eral population at age 70 years is 12 years, then his YLL=12, 
YLD=4 (=0.4×10), and the DALY lost=16. Based on egalitari-
an principles, the WHO-GBDP applies the same DW to a spe-
cific health condition irrespective of the individual’s race, gen-
der, occupation, and socioeconomic status.
Age-weighting and future discount
Public health policy modeling usually employs age-weighting 
and future discount rate, and the WHO-GBDP also employs 
these two modeling assumptions in their DALY estimations. 
The age-weighting is to assign different values to different life 
years: higher in young adult ages than in infancy and elderly. 
The higher valuation of young adult life years well reflects the 
public’s choice when only one patient can be treated in a hy-
pothetical situation. The public’s decision might be implicitly 
made based on each individual’s life expectancy, productivity, 
and contribution to the well-being of others.
1
The future discount is to discount the value of future healthy 
life years at present, reflecting that the public values 1 year of 
healthy life in the future less than 1 year of immediate present. 
The future discount is based on several concepts. At the sim-
plest level of an economic concept, most individuals prefer 
present benefits rather than future benefits. At a more complex 
level of the health concept, the uncertainty of survival in the 
future that increases with increasing ages necessitates the fu-
ture discount.
By incorporating age-weighting and future discount, YLL, 
YLD, and DALY are calculated using the following formula:1 
DALY[r, K] =YLL[r, K]+YLD[r, K]
YLL[r, K]=KCe
rA/(r+β)2{e
-(r+β)(L+A)[-(r+β)(L+A)-1]
-e
-(r+β)A[-(r+β)A-1]}+[(1-K)/r](1-e
-rL) 
YLD[r, K]=DKCe
rAs/(r+β)2{e
-(r+β)(Ld+As)[-(r+β)(Ld+As) 
-1]-e
-(r+β)As[-(r+β)As-1]}+[(1-K)/r](1-e
-rLd)
where K is the age-weighting modulation factor (K=1), β is 
the parameter for the age-weighting function (β =0.04), r is 
the discount rate (r=0.03), C is a constant (C=0.1658), A is the 
age of death, L is the life expectancy of the general popula-
tion at age A, D is the disability weight, As is the age at stroke, 
Ld is the duration of disability with a mRS X state (=life ex-
pectancy of a stroke patient with a disability of mRS X at 
age As). Note that the WHO-GBDP employs an annual 3% 
discount rate (r=0.03) for future discount; when age weight-
ing is considered, this gives K=1 and β=0.04.
1
DW for each mRS disability rank
Poststroke disability spans a wide spectrum. Previously, the 
WHO-GBDP has provided only two DWs for stroke, 0.920 
for acute stroke and 0.266 for chronic poststroke states.
3 Since 
most contemporary stroke research employs the mRS as an 
outcome measure, the generation of a DW for each mRS dis-
ability level would be the first step to enable the application of 
DALY to diverse stroke research.
A recent study has determined the DWs for individual mRS 
levels,
6 using person-trade-off methodology, which is the stan-
dard technique employed by the WHO-GBDP.
1 Multinational 
stroke neurologists participating in that study were asked to 
assume that they were allocating health system resources and 
to decide what number would make them indifferent between 
the choices of extending the lives of 1,000 healthy people for 
1 year versus extending the lives of N stroke survivors with a 
disability of mRS X for 1 year. Using the modified Delphi 
process, the value of N for each mRS was generated after 
achieving a substantial consensus. The DW for each mRS was Hong KS
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derived by converting the value of N using the formula: DW= 
1-1,000/N. Finally, the derived DWs were normalized to the 
WHO-GBDP unitary chronic DW of 0.266 to ensure compa-
rability of the newly derived DWs to the DWs of other health 
conditions. As a result, the adjusted DW of each mRS was de-
termined as 0, 0.053, 0.228, 0.353, 0.691, 0.998, and 1 for mRS 
0-6, respectively. The DW for each mRS confirms that the 
mRS is not a continuous, equally spaced scale, but rather a 
rank-ordered, unequally spaced scale. Consonant with the 
perception of stroke experts, the mRS ranks can be subcatego-
rized into four groups based on the DWs: mRS 0-1 as no or 
minimal disability, (DW range 0-0.053), mRS 2-3 as mild to 
moderate disability (DW range 0.228-0.353), mRS 4 as se-
vere disability (DW of 0.691), mRS 5-6 as extreme disability 
or death (DW range 0.998-1) (Fig. 1).
Estimation of life expectancy for individual  
stroke survivors
To calculate the DALY lost for individual stroke survivors, 
each patient’s life expectancy needs to be estimated. Recent 
studies have demonstrated that long-term life expectancy de-
creases monotonically as the mRS level increases.
9,10 From the 
data of these studies, we derived mortality hazard ratios for 
each mRS status relative to the general population.
7 Then, by 
multiplying the mRS-specific mortality HR and age-specific 
mortality rates of the general population provided in life ta-
bles, we generated stroke survivors’ age-specific mortality 
rates and life tables for each gender and mRS state. From the 
stroke survivors’ life tables, the life expectancy for each stroke 
survivor can be determined based on their age, gender and 
mRS state. As a result, this novel technique enables the calcu-
lation of DALY lost for each patient and to apply the DALY 
metric to individual patient-level data analyses. 
Acute stroke trial
To demonstrate the application of DALY to individual-patient 
data analysis in acute stroke trials, we reanalyzed the National 
Institute of Neurological Disorders and Stroke Tissue Plasmin-
ogen Activator trials. That study demonstrated that intrave-
nous TPA therapy administered within 3 hours saves on aver-
age 1.28 healthy life years, and 4.4 healthy life years for 
patients who benefit from the treatment.
7
The DALY analysis has several advantages over convention-
al analyses. The DALY value indicates the saving of healthy 
life years conferred by a treatment, and is therefore more un-
derstandable for the layperson. Acute stroke trials usually em-
ploy stroke specific functional outcome scales (i.e., mRS out-
come scale). These are familiar to stroke experts, but unfami-
liar to the layperson. Therefore, when findings are provided 
in an mRS analysis, public and health-policy decision-makers 
have difficulty interpreting the results of acute stroke trials and 
deciding upon health policies and treatment choice. In addition, 
the DALY metric allows physicians to communicate treatment 
effect tailored to individual patients. For example, suppose that 
a 50-year-old Korean man with a severe ischemic stroke is 
expected to be bedridden (mRS 5) without successful reperfu-
sion therapy, his DALY lost would be 16.77. If this patient had 
successful reperfusion therapy and a disability of mRS 1, the 
DALY lost would be 3.13 and the treatment could confer 13.64 
years of healthy life.
The DALY is a continuous interval scale. In general, contin-
uous scales are more advantageous in statistical power detect-
ing treatment effect than ordinal scales. In acute stroke trials, 
the mRS has been the most widely employed outcome scale. 
Since the mRS is an ordinal scale, conventional analytic tech-
niques have employed mRS dichotomization using an cutoff 
point. The usual cutoff points are mRS 0-1 or mRS 0-2 which 
indicate excellent or good outcomes, respectively. While the 
dichotomized mRS analysis has the advantage of simple clin-
ical interpretation for stroke experts, it collapses distinct mRS 
levels into only two outcome categories and inevitably discards 
the original, detailed mRS outcome information. In addition, 
determination of the cutoff point is somewhat arbitrary, and a 
negative trial might be attributable to selecting an inappropri-
ate cutoff point rather than inefficacy of a treatment tested. The 
ECASS (European Cooperative Acute Stroke Study) II that 
tested intravenous TPA efficacy would have yielded a positive 
result if mRS 0-2 had been selected as a primary endpoint.
11 In 
contrast, the Japanese MELT (Middle Cerebral Artery Embo-
lism Local Fibrinolytic Intervention) trial that tested intra-arte-
rial thrombolysis would have yielded a positive result if the 
mRS 0-1 had been a primary endpoint.
12 The greater statistical 
power of the continuous DALY metric over conventional mRS 
dichotomization analysis has been well demonstrated in the age 
subgroup analysis of the National Institute of Neurological 
Disorders and Stroke Tissue Plasminogen Activator trials, in 
Fig. 1. Disability weight for each mRS level. mRS: modified Rankin 
Scale.
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which the TPA effect for the aged 70 years or more was consis-
tently significant with DALY analyses but not with dichoto-
mized analyses.
7
Finally, conventional stroke outcome scales are one-time, 
snapshot metrics and implicitly index the burden of disability 
for patients’ remaining life. In contrast, the DALY metric ex-
plicitly indicates this burden by directly measuring the life 
years lost due to disability for their remaining life. Standard 
measures value the severe disability states of young and very 
elderly stroke patients equally, which is at variance with the 
public’s perception. However, the DALY metric can discrimi-
nate the poststroke burdens among various age groups by re-
flecting the differential duration of disability.
Complication impact on stroke outcome
Organized stroke care provides clear benefits but requires ad-
ditional human and structural resources. The benefits of orga-
nized stroke care are partially attributable to reducing post-
stroke complications that increase disability and mortality.
13-15 
To guide a transparent and scientific decision in allocating re-
sources to competing health interventions, stroke experts must 
delineate for public and health policy decision-makers the im-
pact of poststroke complications with a validated common 
metric that ensures comparability across diverse health condi-
tions.
To date, the adverse impact of poststroke complications has 
been delineated based on the increased risk of mortality or 
poor outcome measured by stroke-specific outcome scales. 
The mortality measure allows poststroke complications to be 
compared with other health conditions, but does not fully re-
flect the impact of complications that increase both disability 
and mortality. In contrast, analysis with stroke-specific out-
come scales can reflect the increased disability due to compli-
cations, but does not ensure its comparability to other health 
conditions. In contrast, the DALY metric could incorporate 
both disability and mortality, and ensures comparability since 
it is a universal, time-based metric. 
We previously analyzed stroke registry data that prospec-
tively captured individual-patient mRS outcomes and compli-
cations, and demonstrated that poststroke complications de-
prive patients of approximately 2 years of healthy life. In addi-
tion, a greater number of complications lead to a greater loss 
of healthy life years: 1.52 additional DALY lost with one com-
plication and 2.69 DALY lost with two or more complications 
(Fig. 2).
8
The DALY metric allows stroke experts to describe an in-
terventional benefit in a more understandable manner. A previ-
ous study found that pneumonia developed in about 12% of 
patients and led to about 2-years of healthy life lost.
8 Another 
study demonstrated that formal dysphagia screening and man-
agement could reduce of the incidence of pneumonia by 50%.
16 
Given the annual incidence of 100,000 strokes in Korea,
17 a 
nationwide implementation of dysphagia screening could an-
nually save 12,000 (=100,000×2 years×0.06) healthy life years 
in Korea. 
Weighting of vascular endpoints  
in prevention trials
In vascular prevention trials, the usual primary endpoint is the 
composite of nonfatal stroke, nonfatal myocardial infarction 
(MI), and vascular death. The composite endpoint analysis has 
advantages since it integrates the treatment impact on diverse 
organs and increases the statistical power by increasing the 
number of vascular events. However, a well-recognized limi-
tation is the equal weighting of all vascular events regardless 
of their differential impacts on a patient’s life. The debates re-
garding the findings of the Carotid Revascularization Endar-
terectomy versus Stenting Trial clearly reflect the weakness of 
this equal weighting. That trial concluded that endarterectomy 
and stenting are equally effective. However, the stenting group 
had a higher risk of stroke, while the endarterectomy group had 
a higher risk of MI. Quality-of-life analyses among survivors 
of the Carotid Revascularization Endarterectomy versus Stent-
ing Trial trial at 1 year demonstrated that stroke had a greater 
adverse effect on a broad range of health-status domains than 
did myocardial infarction.
18 Thus, interpreting trial results 
might require differential weighting analysis adjusted for 
health states, but a widely accepted weighting method does 
not currently exist. 
The DALY metric is well suited to assigning differential 
weight to disparate vascular events. Reflecting differential dis-
ability of and life expectancy after each event, the DALY 
method can convert hundreds of health conditions into a uni-
form, patient-centered metric of healthy life years lost. The 
differences in DW and life expectancy between stroke and MI 
survivors have been well recognized. The Framingham study 
Fig. 2. DALY lost relative to to the number of complications. DALY: 
disability-adjusted life years.
0 (n=803)
Number of complications (n = number of patients)
Difference=1.52 (95% CI, 1.15-1.89)
Difference=2.69 (95% CI, 2.18-3.20)
p<0.001
p<0.001
3.10±0.07
4.62±0.18
5.79±0.25
1 (n=230) ≥2 (n=200)
7
6
5
4
3
2
1
0
D
A
L
Y
 
l
o
s
tHong KS
www.thejcn.com  113
showed that at age 60 years, the life expectancies for stroke 
and MI survivors are 8.9 years (men and women combined) 
and 11.2 years, respectively.
19 For the DW generated in our 
previous study, the DW of chronic poststroke state (0.266) 
was about seven times higher than that of the chronic post-MI 
state (0.037).
20 
The DW for chronic poststroke state has previously been 
determined by the WHO-GBDP. The WHO-GBDP did not 
provide a unified DW for the chronic post-MI state, but did 
provide specific DWs for the two major disabling MI sequel-
ae: 0.201 for congestive heart failure (CHF) and 0.124 for an-
gina pectoris (AP). These conditions occur in only a subset of 
post-MI patients: 19.8% for AP and 16.9% for CHF.
21,22 Fur-
thermore, among those with post-MI angina, angina attacks 
occurs daily in only 1.2% of patients, weekly in 3.0% (angina 
symptom per 2-7 days: 81.1 days/year), and less than 1 day/
week for 4 weeks in 15.6% (angina attack per 8-28 days: 20.3 
days/year).
21 Since the WHO-GBDP DWs were originally de-
rived under the assumption of chronic and persistent symptoms 
and signs,
1 we determined the unified DW for the chronic 
post-MI state after taking into account these proportions and 
frequencies for angina symptom occurrence using the follow-
ing formula:20 
DWMI=(PCHF×DensityCHF×DWCHF)+(PAP×DensityAP× 
DW AP),
where PCHF or AP is proportion of MI survivors experiencing 
CHF or AP, DensityCHF or AP is the number of days per year that 
these individuals experience symptoms of CHF or AP (days 
divided by 365 days). DensityCHF or AP is calculated using the 
following formula:
DensityAP=[(frequency of daily angina/19.8)×(days of 
symtom/365)]+[(frequency of weekly angina/19.8)×(days of 
symtom/365)]+[(frequency of angina attack less than one 
day per 4 weeks/19.8)×(days of symtom/365)]=0.14. Densi-
tyCHF was determined to be 1.0 under the assumption of daily 
symptoms or disability in daily activities.
By applying the projected life expectancies, expected age at 
death, and DWs to the DALY calculation formula, we derived 
that the DALY lost for those aged 60 years was 11.59 for vas-
cular death (YLD=0 and YLL=11.59), 7.63 for nonfatal stroke 
(YLD=1.69 and YLL=5.94), and 5.14 for nonfatal MI (YLD= 
0.28 and YLL=4.86) (Fig. 3). Our formal analysis indicated 
that compared with a nonfatal MI, the DALY lost is 1.48-fold 
greater for a nonfatal stroke and 2.25-fold greater for a vas-
cular death. Moreover, reflecting the differential DW between 
chronic poststroke and chronic poststroke MI states, the DALY 
analysis could demonstrate the discrete contribution of YLD to 
total DALY lost between the two states: 22.1% for nonfatal 
stroke and 5.4% for nonfatal MI. Consonant with the percep-
tion of experts, this DALY analysis clearly demonstrates that 
the DALY lost due to MI survivors is overwhelmingly deter-
mined by premature mortality rather than MI-related disabil-
ity, while the stroke-related disability contributes more than 
20% to overall healthy life years lost.
Nationwide stroke burden measure
The DALY was originally developed to measure disease bur-
den both globally and regionally. To date, the stroke DALY 
burden in a population has been projected from the incidence, 
prevalence, fatality, mortality, and a unified DW for overall 
stroke. Some unavailable epidemiologic data were derived 
from the DisMod method or projected from data of compara-
ble populations.
23 Since the stroke care system and the charac-
teristics of patients vary across diverse populations, the average 
poststroke disability level is likely to differ between such pop-
ulations. Therefore, population-specific poststroke disability 
levels and incidence data might more finely project stroke bur-
den in a particular population. 
For this purpose, we derived for Korean ischemic stroke pa-
tients the average DALYs lost specific for age groups from the 
data of two large Korean ischemic stroke registries that pro-
spectively captured the 3-month mRS outcomes of all consec-
utive patients.
24 The incidences of ischemic stroke in various 
age groups were obtained from the 2006 report of Construc-
tion of National Surveillance System for Cardiovascular and 
Cerebrovascular Diseases.
17 The nationwide DALY lost for 
each age group was generated by multiplying the average 
DALY lost and incidence for each group: 9,952 for those aged 
≤44 years, 24,608 for 45-54 years, 50,682 for 55-64 years, 
88,875 for 65-74 years, 18,118 for 75-84 years, and 4,735 for 
≥ 85 years. Accordingly, the annual burden due to 64,688 isch-
emic strokes in 2004 was estimated to be 234,399 DALY lost. 
The group of those aged 65-74 years ranked in the first place.
24
By integrating the DALY values from stroke registries cap-
turing detailed individual-patient information and the inci-
dence from a nationwide database, we obtained a more refined 
Fig. 3. DALY lost and relative contribution of YLL and YLD for each 
vascular event. DALY: disability-adjusted life years, YLD: years of 
healthy life lost due to disability, YLL: years of life lost due to prema-
ture death.
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DALY burden due to ischemic stroke that will help to guide 
health policy planning. More than 230,000 healthy life years 
were lost annually to ischemic stroke in Korea. To reduce the 
stroke burden, the first target population would be those aged 
65-74 years who contribute the greatest burden to the total 
DALY lost for ischemic stroke (almost 40%). 
Conclusion
The DALY approach has a strong methodological framework 
and a firm theoretical grounding. It has been widely accepted 
by public health experts and employed to measure the global 
and regional burdens of disease. Recent advances in the stroke 
field expand the application of DALY metric to analyzing 
acute stroke trials, delineating complication impacts, differen-
tial weighting for disparate vascular events, and estimating 
stroke burden in a specific population. Like stroke, most neu-
rological disorders torment human being by imposing both 
disability and mortality. Therefore, the DALY might be wide-
ly applicable not only to stroke but also to other disabling neu-
rological disorders. 
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